References
- Dnyandev GG, Sugandhi VV, Jha SK, et al. Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance. Ageing Res Rev, 2024, 99:102357. doi: 10.1016/j.arr.2024.102357.
- Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci, 2006, 7(4):295-309. doi: 10.1038/nrn1883.
- Hong R, Li X. Discovery of monoamine oxidase inhibitors by medicinal chemistry approaches. Medchemcomm, 2018, 10(1):10-25. doi: 10.1039/c8md00446c.
- Park JH, Ju YH, Choi JW, et al. Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease. Sci Adv, 2019, 5(3):eaav0316. doi: 10.1126/sciadv.aav0316.
- Manzoor S, Hoda N. A comprehensive review of monoamine oxidase inhibitors as anti-Alzheimer’s disease agents: A review. Eur J Med Chem, 2020, 206:112787. doi: 10.1016/j. ejmech.2020.112787.
- Cai Z. Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer’s disease (Review). Mol Med Rep, 2014, 9(5):1533-1541. doi: 10.3892/mmr.2014.2040.
- Burke WJ, Li SW, Schmitt CA, et al. Accumulation of 3,4-di-hydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer’s disease: mechanism of neuron death. Brain Res, 1999, 816(2):633-637. doi: 10.1016/s0006-8993(98)01211-6.
- Knittel J, ltani N, Schreckenberg R, et al. Monoamine Oxi-dase A contributes to serotonin- but not norepinephrine-dependent damage of rat ventricular myocytes. Biomolecules, 2023, 13(6):1013. doi: 10.3390/biom13061013.
- Sung JS, Kim S, Jung J, et al. Monoamine Oxidase-A (MAO-A) inhibitors screened from the autodisplayed Fv-antibody library. ACS Pharmacol Transl Sci, 2023, 7(1):150-160. doi: 10.1021/acsptsci.3c00204.
- Baweja GS, Gupta S, Kumar B, et al. Recent updates on structural insights of MAO-B inhibitors: a review on target-based approach. Mol Divers, 2024, 28(3):1823-1845. doi: 10.1007/s11030-023-10634-6.
- Davis SE, Cirincione AB, Jimenez-Torres AC, Zhu J. The Impact of neurotransmitters on the neurobiology of neurode-generative diseases. lnt J Mol Sci, 2023, 24(20):15340. doi: 10.3390/ijms242015340.
- Dash UC, Bhol NK, Swain SK, et al. Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications. Acta Pharm Sin B, 2025, 15(1):15-34. doi: 10.1016/j.apsb.2024.10.004.
- Gallo A, Pillet LE, Verpillot R. New frontiers in Alzheimer’s disease diagnostic: Monoamines and their derivatives in biological fluids. Exp Gerontol, 2021, 152:111452. doi: 10.1016/j. exger.2021.111452.
- Schedin-Weiss S, lnoue M, Hromadkova L, et al. Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with Y-secretase and regulates neuronal amyloid β-peptide levels. Alzheimers Res Ther, 2017, 9(1):57. doi: 10.1186/s13195-017-0279-1.
- Jaisa-Aad M, Muñoz-Castro C, Healey MA, et al. Characterization of monoamine oxidase-B (MAO-B) as a biomarker of reactive astrogliosis in Alzheimer’s disease and related dementias. Acta Neuropathol, 2024, 147(1):66. doi: 10.1007/s00401-024-02712-2.
- Naffaa MM. Monoamine Oxidase B in astrocytic GABA synthesis: a central mechanism in neurodegeneration and neuro-inflammation. J Cell Signal, 2025, 6(2):53-70.
- Marucci G, Buccioni M, Dal Ben D, et al. Enjcacy of acetylcholinesterase inhibitors in Alzheimer’s disease. Neuropharmacology, 2021, 190:108352. doi: 10.1016/j.neuro-pharm.2020.108352.
- Rahman MS, Uddin MS, Rahman MA, et al. Exploring the role of monoamine oxidase activity in aging and Alzheimer’s Disease. Curr Pharm Des, 2021; 27(38):4017-4029. doi: 10.2 174/1381612827666210612051713.
- Yang DC, Cheng Y, Lin F. NADPH and Alzheimer’s Disease and Parkinson’s Disease. ln: Qin ZH (eds) Biology of Nicotinamide Coenzymes. 2025, Springer, Singapore. https://doi.org/10.1007/978-981-97-9877-3_39.
- Giménez-Xavier P, Gómez-Santos C, Castaño E, et al. The decrease of NAD(P)H has a prominent role in dopamine toxicity. Biochim Biophys Acta, 2006, 1762(5): 564-574. doi: 10.1016/j.bbadis.2006.02.003.
- Kaludercic N, Arusei RJ, Di Lisa F. Recent advances on the role of monoamine oxidases in cardiac pathophysiology. Basic Res Cardiol, 2023, 118(1):41. doi: 10.1007/s00395-023-01012-2.
- lacovino LG, Reis J, Mai A, et al. Diphenylene iodonium is a noncovalent MAO inhibitor: a biochemical and structural analysis. Chem Med Chem, 2020, 15(15):1394-1397. doi: 10.1002/cmdc.202000264.
- Taupin P, Zini S, Cesselin F, et al. Subcellular fractionation on Percoll gradient of mossy fiber synaptosomes: morphological and biochemical characterization in control and degranulated rat hippocampus. J Neurochem, 1994, 62(4):1586-1595. doi: 10.1046/j.1471-4159.1994.62041586.x.
- Mungarro-Menchaca X, Ferrera P, Morán J, Arias C. β-Amyloid peptide induces ultrastructural changes in synaptosomes and potentiates mitochondrial dysfunction in the presence of ryanodine. J Neurosci Res, 2002, 68(1):89-96. doi: 10.1002/jnr.10193.
- Robyt JF, Ackerman RJ, Chittenden CG. Reaction of protein disulfide groups with Ellman’s reagent: A case study of the number of sulfhydryl and disulfide groups in Aspergillus ory-zae α-amylase, papain, and lysozyme. Arch Biochem Biophys, 1971, 147(1):262-269. doi: 10.1016/0003-9861(71)90334-1.
- Shirani M, Alizadeh S, Mahdavinia M, Dehghani MA. The ameliorative effect of quercetin on bisphenol A-induced toxicity in mitochondria isolated from rats. Environ Sci Poll Res, 2019, 26(8):7688-7696. doi: 10.1007/s11356-018-04119-5.
- Ravindranath V, Anandatheerthavarada HK. Preparation of brain microsomes with cytochrome P450 activity using calcium aggregation method. Anal Biochem, 1990, 187(2):310-313. doi: 10.1016/0003-2697(90)90461-h.
- Mansuy D, Sassi A, Dansette PM, Plat M. A new potent inhibitor of lipid peroxidation in vitro and in vivo, the hepatoprotective drug anisyldithiolthione. Biochem Biophys Res Commun, 1986, 135(3):1015-1021. doi: 10.1016/0006-291x(86)91029-6.
- Bautista-Aguilera OM, Esteban G, Bolea l, et al. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer’s disease. Eur J Med Chem, 2014, 21(75):82-95. doi: 10.1016/j.ej-mech.2013.12.028).
- Georgieva M, Sharkov M, Mateev E, et al. Classical Paal-Knorr cyclization for synthesis of pyrrole-based aryl hydra-zones and in vitro/in vivo evaluation on pharmacological models of Parkinson’s disease. Molecules, 2025, 30: 3154. doi:10.3390/molecules30153154.
- Molinspiration cheminformatics. [lnternet], Accessed on September 2025. Available from: https://www.molinspiration.com/cgi/properties)
- Abagyan R, Totrov M. High-throughput docking for lead generation. Curr Opinion Chem Biol, 200, 5(4):375-382 (https://molsoft.com/mprop/)
- Gupta M, Lee HJ, Barden CJ, Weaver DF. The Blood-Brain Barrier (BBB) score. J Med Chem, 2019, 62(21):9824-9836. doi: 10.1021/acs.jmedchem.9b01220.
- Scotti MT, Herrera-Acevedo C, de Menezes RPB, et al. Mol-PredictX: Online Biological Activity Predictions by Machine Learning Models. Mol lnform, 2022, 41(12):e2200133. doi: 10.1002/minf.202200133.
- Gundersen V. Protein aggregation in Parkinson’s disease: protein aggregation in Parkinson’s Disease.” Acta Neurologica Scandinavica, 2010, 122:82-87. doi: 10.1111/j.1600-0404.2010.01382.x.